John Evans, DO
Interventional Cardiology · Muskogee, OKNPI 1790075034
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,826 of the $16,904 with a category attached, or 64.0%. 34 manufacturers reported payments, led by Medtronic at 46.8% of the total. Reporting peaked in 2019 at $6,840 and has fallen 63.0% since, to $2,531 in 2025.
Across 352 payments — averaging $48.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Boston Scientific$2K
- Abbott$2K
- Abiomed$735
- Bard Peripheral Vascular, Inc.$601
- Philips North America LLC$392
- plus $3K from 28 others
What the payments were for
- Travel & lodging$6,07836%
- Food & beverage$10,82664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 61 | $7,911 |
| Boston Scientific | 48 | $2,416 |
| Abbott | 66 | $2,044 |
| Abiomed | 10 | $735 |
| Bard Peripheral Vascular, Inc. | 11 | $601 |
| Philips North America LLC | 18 | $392 |
| Merck | 17 | $323 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $290 |
| Novartis | 16 | $282 |
| Angiodynamics, Inc. | 11 | $248 |
| Amgen | 7 | $167 |
| Cordis US CORP. | 9 | $165 |
| Boehringer Ingelheim | 8 | $147 |
| Reflow Medical Inc | 9 | $143 |
| Shockwave Medical, Inc | 1 | $142 |
| Biotronik Inc. | 1 | $103 |
| Surmodics, Inc. | 4 | $93 |
| AstraZeneca | 6 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $83 |
| Amarin Pharma, Inc. | 3 | $60 |
| Pfizer | 4 | $57 |
| Kestra Medical Technology Services, Inc. | 2 | $50 |
| Inari Medical, Inc. | 3 | $41 |
| Nuwellis, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $36 |
| Cathworks, Inc. | 1 | $27 |
| GE HealthCare | 1 | $25 |
| Atricure, Inc. | 1 | $21 |
| Cagent Vascular Inc | 1 | $20 |
| Terumo Medical Corporation | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Medline Industries LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$3,622
- Reveal LINQ$1,672
- ANGIOJET$977
- Confirm Rx$300
- Rotarex$249
- Impella$245
- ESPRIT$205
- RotarexS 6 F x 135 cm$165
- INCEPTIV$149
- GENERAL - THERAPIES$148
- Claria MRI$143
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- AngioSculpt PV$119
- Assurity Pacemaker$117
How this compares
$16,904 in reported general payments places this provider in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $133,375 |
| EntrestoSacubitril/Valsartan | 87 | $89,432 |
| XareltoRivaroxaban | 43 | $59,635 |
| BrilintaTicagrelor | 71 | $54,187 |
| Ranolazine ErRanolazine | 33 | $3,236 |
| Atorvastatin Calcium | 142 | $2,465 |
| ClopidogrelClopidogrel Bisulfate | 116 | $1,964 |
| Bisoprolol Fumarate | 40 | $1,578 |
| Metoprolol Succinate | 95 | $1,372 |
| Losartan Potassium | 80 | $1,192 |
| Ezetimibe | 28 | $1,190 |
| Rosuvastatin Calcium | 54 | $1,136 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 54 | $1,037 |
| Carvedilol | 107 | $877 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 45 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $133,375168 claims |
| NovartisEntresto | $282 | $89,43287 claims |
| Johnson & JohnsonXarelto | $36 | $59,63543 claims |
| AstraZenecaBrilinta | $93 | $54,18771 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Muskogee
- Jack CasasMuskogee$21K
- Bryan LucentaMuskogee$10K
- Kamran MuhammadTulsa$1.4M
- George ChrysantOklahoma City$524K
- Suresh ChandrasekaranMidwest City$302K
- Jeffrey SparlingOklahoma City$231K
- Stanley ZimmermanTulsa$93K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Matthew ComstockTulsa$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.